Aragen Life Sciences, a prominent player in the biotechnology sector, is headquartered in India and operates extensively across major regions, including North America and Europe. Founded in 2000, the company has established itself as a leader in providing integrated solutions for drug discovery, development, and manufacturing.
Aragen's core offerings encompass a wide range of services, including biologics, small molecules, and custom research, distinguished by their commitment to innovation and quality. The company has achieved significant milestones, such as expanding its capabilities in biologics and securing partnerships with leading pharmaceutical firms.
With a strong market position, Aragen Life Sciences is recognised for its expertise and reliability, making it a preferred partner for clients seeking comprehensive life science solutions.
+48 vs industry average
Aragen Life Sciences’s score of 77 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Aragen Life Sciences?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Research Services has typical carbon intensity
Industry performance
The Research Services industry has increased its overall emissions by 17% since 2019
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Aragen Life Sciences's reported carbon emissions
In 2025, Aragen Life Sciences reported total greenhouse gas emissions of approximately 63,000,000 kg CO2e, comprising 7,636,000 kg CO2e from Scope 1, 42,130,000 kg CO2e from Scope 2, and 47,682,540 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its carbon footprint, aiming for a 50.4% reduction in absolute Scope 1, 2, and 3 emissions by FY2033, using FY2023 as the base year. Additionally, Aragen is committed to achieving net-zero emissions across all scopes by FY2050. The near-term targets include a 20% reduction in CO2 emissions intensity for both Scope 1 and Scope 2 by 2025 compared to 2021 levels. These commitments align with the Government of India's goals under the Paris Agreement, demonstrating Aragen's dedication to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Aragen Life Sciences’s Climate Goals (2030 & 2050)
3 goals2033
50.4% reduction in all scopes
Near-Term Targets: Aragen Life Sciences Limited commits to reduce absolute scope 1 and 2 GHG emissions 50.4% by FY2033 from a FY2023 base ye…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 3 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
10 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Aragen Life Sciences
Frequently asked questions
Common questions about Aragen Life Sciences’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project